By Sabela Ojea
Applied Therapeutics said it has received a complete response letter from the Food and Drug Administration related to its new drug application for govorestat due to deficiencies in the clinical application.
Shares dropped 16% to $8.57 in post-marketing trading. Through Wednesday's close, the stock has more-than-doubled since the beginning of the year.
The FDA issues a complete response letter when it decides not to approve a new drug application in its present form.
The biopharmaceutical company on Wednesday said it is reviewing the feedback from the FDA and plans to immediately request a meeting to potentially resubmit the NDA for the treatment of galactosemia or appeal the decision along with appropriate next steps.
"We are disappointed by the FDA's decision today," Chief Executive Shoshana Shendelman said.
Galactosemia is a progressive and debilitating disease without any existing treatment options, the executive added.
Overall, Galactosemia a rare genetic disorder that prevents the body from processing galactose.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 27, 2024 16:33 ET (21:33 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.